What is the share price of Dishman Carbogen Amcis Ltd (DCAL) today?
The share price of DCAL as on 24th April 2025 is ₹215.43. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Dishman Carbogen Amcis Ltd (DCAL) share?
The past returns of Dishman Carbogen Amcis Ltd (DCAL) share are- Past 1 week: 0.93%
- Past 1 month: -9.44%
- Past 3 months: -8.87%
- Past 6 months: 22.45%
- Past 1 year: -7.72%
- Past 3 years: 18.21%
- Past 5 years: 149.20%
What are the peers or stocks similar to Dishman Carbogen Amcis Ltd (DCAL)?
The peers or stocks similar to Dishman Carbogen Amcis Ltd (DCAL) include:What is the market cap of Dishman Carbogen Amcis Ltd (DCAL) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Dishman Carbogen Amcis Ltd (DCAL) is ₹3275.51 Cr as of 24th April 2025.What is the 52 week high and low of Dishman Carbogen Amcis Ltd (DCAL) share?
The 52-week high of Dishman Carbogen Amcis Ltd (DCAL) is ₹307.98 and the 52-week low is ₹133.What is the PE and PB ratio of Dishman Carbogen Amcis Ltd (DCAL) stock?
The P/E (price-to-earnings) ratio of Dishman Carbogen Amcis Ltd (DCAL) is -21.35. The P/B (price-to-book) ratio is 0.58.Which sector does Dishman Carbogen Amcis Ltd (DCAL) belong to?
Dishman Carbogen Amcis Ltd (DCAL) belongs to the Health Care sector & Labs & Life Sciences Services sub-sector.How to buy Dishman Carbogen Amcis Ltd (DCAL) shares?
You can directly buy Dishman Carbogen Amcis Ltd (DCAL) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Dishman Carbogen Amcis Ltd
DCAL Share Price
215.433.12% (+6.51)
DCAL Share Price Chart
High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
DCAL Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
DCAL Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| -29.84 | 0.58 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 50.61 | 6.44 | 0.53% |
DCAL Analyst Ratings & Forecast
Detailed Forecast —
Forecast data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
DCAL Company Profile
Dishman Carbogen Amicis Limited is an India-based contract research and manufacturing services (CRAMS) company. The Company is engaged in the process of research and development to late-stage clinical and commercial manufacturing
Investor Presentation
View olderDCAL Similar Stocks (Peers)
Compare with peersDIVISLAB
PE Ratio
98.30
1Y Return
62.97%
Buy Reco %
43.48
SYNGENE
PE Ratio
58.96
1Y Return
5.85%
Buy Reco %
75.00
AARTIPHARM
PE Ratio
30.80
1Y Return
45.09%
Buy Reco %
—
VIMTALABS
PE Ratio
56.83
1Y Return
126.43%
Buy Reco %
100.00
BROOKS
PE Ratio
-21.16
1Y Return
40.45%
Buy Reco %
—
DCAL Forecasts
Price
Revenue
Earnings
DCAL Share Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeDCAL Company Revenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeDCAL Stock EPS (Earnings Per Share) Forecast
Hmm, looks like data is unavailable here. Please come back after some timeDCAL
Income
Balance Sheet
Cash Flow
Annual Normal View
DCAL Income Statement
Annual Normal View
| Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1,739.82 | 1,740.48 | 2,112.42 | 2,088.06 | 1,950.48 | 2,184.11 | 2,440.69 | 2,643.98 | 2,672.78 | |||||||||
Raw Materials | 329.58 | 402.19 | 378.01 | 476.38 | 434.77 | 460.50 | 630.40 | 601.21 | 2,282.43 | |||||||||
| Power & Fuel Cost | 49.47 | 48.33 | 56.14 | 60.26 | 41.87 | 62.73 | 87.83 | 104.31 | ||||||||||
| Employee Cost | 596.02 | 625.40 | 714.64 | 762.27 | 872.91 | 981.49 | 1,029.86 | 1,208.16 | ||||||||||
| Selling & Administrative Expenses | 147.69 | 136.29 | 190.73 | 124.58 | 113.81 | 147.71 | 197.66 | 205.53 | ||||||||||
| Operating & Other expenses | 138.47 | 37.23 | 167.18 | 122.55 | 196.60 | 171.53 | 183.12 | 216.20 | ||||||||||
EBITDA | 478.59 | 491.04 | 605.72 | 542.02 | 290.52 | 360.15 | 311.82 | 308.57 | 390.35 | |||||||||
| Depreciation/Amortization | 213.50 | 211.42 | 240.38 | 282.87 | 307.94 | 307.59 | 280.72 | 310.86 | 299.65 | |||||||||
| PBIT | 265.09 | 279.62 | 365.34 | 259.15 | -17.42 | 52.56 | 31.10 | -2.29 | 90.70 | |||||||||
| Interest & Other Items | 49.01 | 48.83 | 56.55 | 61.95 | 47.61 | 56.81 | 85.69 | 119.97 | 148.29 | |||||||||
| PBT | 216.08 | 230.79 | 308.79 | 197.20 | -65.03 | -4.25 | -54.59 | -122.26 | -57.59 | |||||||||
| Taxes & Other Items | 70.65 | 76.22 | 98.46 | 38.69 | 100.10 | -22.26 | -24.79 | 31.19 | 52.18 | |||||||||
| Net Income | 145.43 | 154.57 | 210.33 | 158.51 | -165.13 | 18.01 | -29.80 | -153.45 | -109.77 | |||||||||
| EPS | — | 19.15 | 13.03 | 9.96 | -10.53 | 1.15 | -1.90 | -9.79 | -7.00 | |||||||||
| DPS | 1.20 | 0.00 | 0.20 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||||||
| Payout ratio | — | 0.00 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
DCAL Company Updates
FY 2017
Annual report
PDFFY 2018
Annual report
PDFFY 2019
Annual report
PDFFY 2020
Annual report
PDFFY 2021
Annual report
PDFFY 2024
Annual report
PDFFY 2025
Investor Presentation
Feb 12PDF
Nov 13PDF
DCAL Past Performance & Peer Comparison
Comparing 3 stocks from
Health CareLabs & Life Sciences Services
Compare valuation on Screener
Health CareLabs & Life Sciences Services
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Dishman Carbogen Amcis Ltd | -21.35 | 0.58 | — |
| Divi's Laboratories Ltd | 98.30 | 11.59 | 0.51% |
| Syngene International Ltd | 58.96 | 7.06 | 0.17% |
| Aarti Pharmalabs Ltd | 30.80 | 3.80 | 0.41% |
DCAL Stock Price Comparison
Compare DCAL with any stock or ETFCompare DCAL with any stock or ETF
DCAL
DCAL Shareholdings
DCAL Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
DCAL Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
DCAL Shareholding Pattern
DCAL Shareholding History
Foreign Institutions
Mutual Funds Invested in DCAL
A list of mutual funds holding the stock, ranked on the basis of Market-cap held which is calculated as the value of stock held in the portfolio divided by its market cap
Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding Dishman Carbogen Amcis Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 0.9814% | Percentage of the fund’s portfolio invested in the stock 0.71% | Change in the portfolio weight of the stock over the last 3 months -0.08% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 40/91 (-5) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.1180% | Percentage of the fund’s portfolio invested in the stock 0.21% | Change in the portfolio weight of the stock over the last 3 months -0.02% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 144/316 (-8) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.0006% | Percentage of the fund’s portfolio invested in the stock 0.01% | Change in the portfolio weight of the stock over the last 3 months -0.00% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 172/811 (-51) |
Compare 3-month MF holding change on Screener
smallcases containing DCAL stock
Looks like this stock is not in any smallcase yet.
DCAL Events
DCAL Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
DCAL has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
DCAL Upcoming Dividends
No upcoming dividends are available
DCAL Past Dividends
Cash Dividend
Ex DateEx DateSep 12, 2019
Final
Final | Div/Share: ₹0.20
Dividend/Share
₹0.20
Ex DateEx Date
Sep 12, 2019
DCAL Stock News & Opinions
Articles & Videos
Corporate
Dishman Carbogen Amcis' Shanghai facility clears China regulatory compliance
Dishman Carbogen Amcis announced that its Shanghai facility has successfully obtained its first Drug Manufacturing License (DML) from China's National Medical Products Administration (NMPA). The NMPA approval followed a rigorous review focused on GMP compliance and operational readiness. The Shanghai site successfully met all regulatory expectations, reflecting the maturing of its operations and the strength of its quality systems. This milestone marks a pivotal step in CARBOGEN AMCIS' expansion in China and reinforces its commitment to customers in the region. Located in the Shanghai Chemical Industry Park (SCIP), the 40,000m' site is a fully self-supporting facility equipped for early-phase research and development, pilot scale production and commercial GMP manufacture. Its services range from raw materials to APIs, including high potency material handling and micronization. With equipment in four segregated units and reactor capacities from 50 to 6,300 litres, the facility is built for flexibility, efficiency and scalability. The site employs over 140 people and brings together an international team of specialists whose expertise, combined with advanced infrastructure, enables the delivery of tailored, scalable solutions to customers worldwide. Powered by Capital Market - Live
2 days agoCapital Market - Live
Corporate
Dishman Carbogen Amcis receives affirmation in credit ratings
Dishman Carbogen Amcis has received affirmation in credit ratings from India Ratings and Research at IND A+; Stable/ IND A1+ for various debt facilities availed by the company. Powered by Capital Market - Live
1 week agoCapital Market - Live
Corporate
Dishman Carbogen Amcis allots NCDs aggregating Rs 50 cr
Dishman Carbogen Amcis has allotted 5,000 Rated, Listed, Senior, Secured, Redeemable, Taxable Non-Convertible Debentures of face value of Rs. 1,00,000 each, aggregating to Rs 50 crore on private placement basis. Powered by Capital Market - Live
4 weeks agoCapital Market - Live
Corporate
Dishman Carbogen Amcis to hold board meeting
Dishman Carbogen Amcis will hold a meeting of the Board of Directors of the Company on 12 March 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Dishman Carbogen Amcis reports consolidated net profit of Rs 4.63 crore in the December 2024 quarter
Net profit of Dishman Carbogen Amcis reported to Rs 4.63 crore in the quarter ended December 2024 as against net loss of Rs 59.63 crore during the previous quarter ended December 2023. Sales rose 4.80% to Rs 682.34 crore in the quarter ended December 2024 as against Rs 651.09 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales682.34651.09 5 OPM %20.546.31 - PBDT96.9814.08 589 PBT25.01-66.29 LP NP4.63-59.63 LP Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Dishman Carbogen Amcis to announce Quarterly Result
Dishman Carbogen Amcis will hold a meeting of the Board of Directors of the Company on 12 February 2025.Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Dishman Carbogen Amcis announces of change in CEO of Carbogen Amcis entities
Dishman Carbogen Amcis announced that Pascal Villemagne, CEO of Carbogen Amcis entities (company's wholly owned subsidiaries) has announced his intent to step down at the end of March 2025, to take on a new challenge in his professional career. He will remain in his role until 31 March 2025. Further, the company announced that Stephan Fritschi, currently serving as Chief Alliance Officer and deputy CEO, will assume the role of CEO, effective as of 01 April 2025.Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Carbogen Amics AG successfully completes Swissmedic inspection of its Vionnaz facility
Dishman Carbogen Amcis announced that its wholly owned subsidiary based in Switzerland, Carbogen Amics AG has successfully completed a Swissmedic inspection of its Vionnaz facility, reaffirming the site's compliance with high regulatory standards. Swissmedic, the Swiss Agency for Therapeutic Products, conducted a routine two-day inspection at the company's Vionnaz site in Switzerland from 13 to 14 November 2024. Led by an inspector from the Regional Medicines Inspectorate of Western Switzerland (ISOPTh), the inspection focused on the Quality Management System compliance for the development and manufacture of highly potent APIs, including analytical and quality control processes. The site's GMP Certification has been successfully renewed. Powered by Capital Market - Live
3 months agoCapital Market - Live
Earnings
Dishman Carbogen Amcis reports consolidated net profit of Rs 33.09 crore in the September 2024 quarter
Net profit of Dishman Carbogen Amcis reported to Rs 33.09 crore in the quarter ended September 2024 as against net loss of Rs 40.90 crore during the previous quarter ended September 2023. Sales rose 34.51% to Rs 789.04 crore in the quarter ended September 2024 as against Rs 586.59 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales789.04586.59 35 OPM %18.6510.37 - PBDT117.1741.83 180 PBT45.08-33.21 LP NP33.09-40.90 LP Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Dishman Carbogen Amcis to conduct board meeting
Dishman Carbogen Amcis will hold a meeting of the Board of Directors of the Company on 13 November 2024Powered by Capital Market - Live
5 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 4.59%, vs industry avg of 4.52%
Over the last 5 years, market share decreased from 17.16% to 14.95%